Idexx Laboratories

HHAeXchange Names Industry Veteran, Tim Brewer, Chief Technology Officer

Retrieved on: 
Tuesday, September 12, 2023
Laboratory, Medicaid, MCO, General Dynamics, United Kingdom Homecare Association, DXC, Idexx Laboratories, Growth, Principal, Caregiver, Health insurance, Online shopping, Management, Brewing, Covetrus

NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- HHAeXchange, a leading provider of homecare management solutions for providers, managed care organizations (MCOs), and state Medicaid agencies, today announced it has named technology veteran, Tim Brewer, as the company's Chief Technology Officer (CTO). The strategic hire further advances HHAeXchange's commitment to transforming how caregivers, families, providers, and payers operate and deliver homecare.

Key Points: 
  • The appointment of its new CTO underscores HHAeXchange's commitment to delivering innovative, best-in-class technology to homecare payers and providers
    NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- HHAeXchange , a leading provider of homecare management solutions for providers, managed care organizations (MCOs), and state Medicaid agencies, today announced it has named technology veteran, Tim Brewer , as the company's Chief Technology Officer (CTO).
  • The strategic hire further advances HHAeXchange's commitment to transforming how caregivers, families, providers, and payers operate and deliver homecare.
  • A tenured leader in the technology, product development, and healthcare industry with more than 30 years of experience, Brewer most recently served as Principal of Unleash Innovations.
  • His extensive entrepreneurial and technology background has allowed him to focus on scaling business ingenuity and growth within the healthcare sector.

Global Veterinary Biomarkers Market Size/Share Envisaged to Reach USD 2,554.79 Million By 2032, at CAGR 12.3%: Polaris Market Research

Retrieved on: 
Thursday, August 31, 2023
Urbanization, American Veterinary Medical Association, Laboratory, Human, Animal, Pet, Prevalence, AVMA, Veterinarian, Cancer, Livestock, Research, Infection, American Kennel Club, Biomarker, Product type, Element, USD, Government, Detail, HIV disease progression rates, American Pet Products Association, Dog, Government agency, Cattle, Growth, Diagnosis, AKC, Disease, Idexx Laboratories, Cat, Geography, Pharmaceutical industry, Online shopping, Pet industry, Medical imaging, Vaccine, Veterinary medicine, Zoetis, Application, Merck, Virbac

Explore customized purchase options

Key Points: 
  • Explore customized purchase options
    R&D by companies: Rising emphasis on increasing research and development activities by leading companies to improve biomarker portfolios is fueling the veterinary biomarkers market growth.
  • Also, the rising trend of adopting pets from shelters and rescue organizations is boosting the veterinary biomarkers market growth.
  • Cases of cancer and cardiovascular diseases: Veterinary biomarkers are used in veterinary applications to detect and diagnose diseases in the initial stages.
  • Polaris Market Research has segmented the veterinary biomarkers market report based on animal type, product type, application, disease type, and region:

IDEXX Laboratories Announces Second Quarter Results

Retrieved on: 
Tuesday, August 1, 2023
Professional Services, Engineering, Health, Business, Manufacturing, Pharmaceutical, Biotechnology, Pressure, Laboratory, International, Idexx Laboratories, Livestock, LPD, CAG, Investment, IDXX, Pet, Growth, EPS, Software, Pharmaceutical industry, Renewable energy, Tourism, Video game, Cryptocurrency

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.
  • IDEXX innovation and commercial engagement drove record second quarter global premium instrument placements, supporting 11% annual growth in IDEXX's global premium instrument installed base.
  • Second quarter earnings per diluted share (“EPS”) were $2.67, an increase of 71% as reported and 77% on a comparable basis, including 54% growth benefit from lapping prior year discrete R&D investments in the second quarter of 2022.
  • "Strong execution by IDEXX commercial and operational teams drove excellent growth results and financial performance in the second quarter," said Jay Mazelsky, President and Chief Executive Officer.

IDEXX Releases 2022 Corporate Responsibility Report, Providing Environmental, Social, and Governance Updates

Retrieved on: 
Tuesday, July 25, 2023
Laboratory, Corporate social responsibility, Test management, Woman, Idexx Laboratories, GHG, Task force, Sustainability accounting, Animal, IDXX, Sustainability Accounting Standards Board, Corporation, Pet, ESG, Task Force on Climate Related Financial Disclosures, Renewable energy, Veterinary medicine, Management

WESTBROOK, Maine, July 25, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2022 Corporate Responsibility Report, highlighting progress against the environmental, social, and governance (ESG) goals it announced last year. The report also introduces a framework to focus and prioritize the company's ESG goals and initiatives. The framework includes three pillars focused on the environmental and social priorities most important to IDEXX's stakeholders and business, underpinned by strong governance, policies, and systems infrastructure.

Key Points: 
  • IDEXX brings clarity to a complex world through diagnostic and software solutions to support longer, fuller lives for pets and those who care for them.
  • Key highlights from the 2022 report include these:
    Outlined greenhouse gas (GHG) emissions reduction strategy, including key long-term projects that will help IDEXX reach its goals established in 2022.
  • "This year's report coincides with IDEXX celebrating its 40th anniversary," said Jay Mazelsky, IDEXX President and Chief Executive Officer.
  • Read the 2022 Corporate Responsibility Report here .

First Watch Announces Appointment of Irene Chang Britt to Board of Directors

Retrieved on: 
Wednesday, July 19, 2023
Laboratory, Virginia Press Women Inc, Brighthouse Financial, Senior, Campbell Soup Company, CPG, National Association of Corporate Directors, Pepperidge Farm, Drink, History, Bright House, First Watch, LEAP, Divisional patent application, VSCO, IDXX, Lunch, Sunoco, Corporation, NACD, Knowledge, Growth, National Association, NYSE, Idexx Laboratories, Tailored Brands, Management, Entertainment, TerraVia

BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately.

Key Points: 
  • BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately.
  • “We are thrilled to welcome Irene to the Board of Directors of First Watch, and I’m confident that our company will benefit greatly from her expertise,” said Ralph Alvarez, Chairman of the Board of Directors of First Watch.
  • Before joining Campbell Soup, Ms. Chang Britt held a number of leadership positions within Kraft Foods / Nabisco in both the U.S. and Canada.
  • Ms. Chang Britt joins fellow Board of Directors members Ralph Alvarez, Julie Bradley, Tricia Glynn, William Kussell, Stephanie Lilak, David Paresky and Chris Tomasso.

IDEXX Laboratories Elects Irene Chang Britt to Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Veterinary, Technology, Engineering, Professional Services, Business, Software, Manufacturing, Biotechnology, Pharmaceutical, Health, University, Laboratory, Brighthouse Financial, Senior, Kraft Foods, Campbell Soup Company, Toronto, Clothing, Idexx Laboratories, Livestock, MBA, IDXX, Pet, Nabisco, Our Boarding House, Management, Anthropology

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Irene Chang Britt, a former executive at Campbell Soup Company, to the Company's Board of Directors, effective July 11, 2023.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Irene Chang Britt, a former executive at Campbell Soup Company, to the Company's Board of Directors, effective July 11, 2023.
  • "We are pleased to welcome Irene to the IDEXX Board of Directors," said Larry Kingsley, the Company's Independent Non-Executive Board Chair.
  • "I am excited to join the board of a purpose-driven company focused on pet healthcare innovation," said Ms. Chang Britt.
  • Ms. Chang Britt currently serves as an independent director of Brighthouse Financial, Inc., a provider of annuities and life insurance, and Victoria’s Secret & Co., a clothing and beauty retailer.

IDEXX Laboratories to Release 2023 Second Quarter Financial Results

Retrieved on: 
Thursday, June 29, 2023
Biotechnology, Manufacturing, Professional Services, Health, Business, Pharmaceutical, Pets, Other Manufacturing, Engineering, Consumer, Veterinary, Telephone, Webcast, Laboratory, Idexx Laboratories, IDXX

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 second quarter results for Tuesday, August 1, 2023 before the market opens.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 second quarter results for Tuesday, August 1, 2023 before the market opens.
  • Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2023 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors .
  • IDEXX Laboratories, Inc. will host its 2023 Investor Day on Thursday, August 10, 2023 at its corporate headquarters in Westbrook, Maine from approximately 8:00 am to 12:00 pm (ET).
  • Additional information on IDEXX’s Investor Day will be provided closer to the date of the event.

IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Retrieved on: 
Thursday, June 15, 2023
Cystatin, Laboratory, Chronic kidney disease, Urine, Creatinine, Veterinarian, Acute kidney injury, Urology, Idexx Laboratories, Biomarker, Patient, IDXX, Nephrology, Dog, Kidney, Diagnosis, Cystatin B, American College, Health, CKD, Kidney disease, Founding, Cat, Dietary supplement, Pharmaceutical industry, Phosphorus, Veterinary medicine

WESTBROOK, Maine, June 15, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the first veterinary diagnostic test for detecting kidney injury in cats and dogs. According to a recent IDEXX survey, as many as one-third of kidney cases seen by veterinarians are related to kidney injury, and a diagnosis can be challenging due to subtle or nonspecific signs.1 The IDEXX Cystatin B Test will be included in test panels assessing renal health, uncovering new clinical insights for an estimated two million patient visits annually. These tests will be run at IDEXX Reference Laboratories starting later this year in the U.S. and Canada, with plans to introduce the test in Europe in 2024.

Key Points: 
  • Together, the IDEXX Cystatin B and IDEXX SDMA® tests offer a comprehensive view of the kidneys by uncovering structural injury and impaired kidney function.
  • The IDEXX expanded renal testing portfolio now includes:
    IDEXX Cystatin B Test, detecting kidney injury with or without changes in kidney function, providing valuable insights in cases such as early toxin exposure.
  • IDEXX SDMA® Test and creatinine, helping to establish a baseline for kidney function for monitoring and early kidney disease detection.
  • For more information on the IDEXX Cystatin B Test and IDEXX kidney health solutions, please visit IDEXX Cystatin B .

Walking Fish Therapeutics Expands Leadership Team

Retrieved on: 
Thursday, June 1, 2023
Emory University, Music, Laboratory, Drug development, Doctor of Pharmacy, University, Senior, Virology, Walking fish, Symyx Technologies, Roche, Bachelor of Technology, Central Electro Chemical Research Institute, Nanotechnology, Electrochemistry, MBA, Infection, Strategic planning, Doctor of Philosophy, MS, University of California, San Diego, Spotlight, Chemistry, University of San Francisco, MD, Walking, SAN, University of Washington Department of Bioengineering, University of California, Berkeley, Five-prime cap, Therapy, Chemical engineering, Idexx Laboratories, Automation, Management, Genentech

SOUTH SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Walking Fish Therapeutics, a leader in B cell engineering, today announced the promotion of Julie Kim, PharmD, MS, to Chief Business Officer. In this new position, Dr. Kim will lead Walking Fish’s business development endeavors and coordinate the company’s external alliances and strategic planning processes.

Key Points: 
  • SOUTH SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Walking Fish Therapeutics, a leader in B cell engineering, today announced the promotion of Julie Kim, PharmD, MS, to Chief Business Officer.
  • “We are delighted to announce the expansion of Julie’s role with Walking Fish,” said Lewis (Rusty) Williams, MD, PhD, co-founder and CEO of Walking Fish Therapeutics.
  • Prior to Walking Fish Therapeutics, she served as Vice President at Quan Capital, responsible for execution and management of biotech investments and served as board observer to several start-up companies, including Walking Fish Therapeutics.
  • Dr. Arvindan joins Walking Fish as Chief Technology Officer, from Spotlight Therapeutics, where he served as Executive Vice President and Chief Technology Officer.

Cristina Zenati Costanzo Named Global Chief People Officer at EasyVista

Retrieved on: 
Tuesday, May 16, 2023
Software, Mobile, Wireless, Networks, Internet, Professional Services, Electronic Design Automation, Fintech, Data Management, Technology, Security, Human Resources, Telecommunications, Laboratory, Partnership, Human resource management, Telindus, Executive Committee, CCEO, CFO, Growth, Popular Executive Committee of Valencia, CPO, Employee experience design, ITSM, Idexx Laboratories, Management

EasyVista, one of the leading providers of ITSM and ITOM solutions, announces the arrival of Cristina Zenati Costanzo as the new Global Chief People Officer — another instrumental change led by CEO Patrice Barbedette.

Key Points: 
  • EasyVista, one of the leading providers of ITSM and ITOM solutions, announces the arrival of Cristina Zenati Costanzo as the new Global Chief People Officer — another instrumental change led by CEO Patrice Barbedette.
  • Cristina Zenati Costanzo explains, “Joining EasyVista at this stage of its global transformation is a tremendous opportunity.
  • Most recently, Zenati Costanzo worked with Telindus, Novidys, Exaprobe, and IDEXX Laboratories before joining with EasyVista in March.
  • Learn more about CPO Cristina Zenati Costanzo